Payment overview · 2025
General Payments
$2,357.07
108 reported records · 23 companies
Healthcare provider profile · identity verified
Rick G Hummel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ST LOUIS, MO · NPI 1609955483
Verified facts
What the public records show
CMS Open Payments records show Rick G Hummel, MD received $2,357.07 in general payments during 2025 across 108 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Entresto, Mounjaro, Movantik, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Entresto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xolair by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Eliquis by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $553.98 | 23.5% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $212.57 | 9.0% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $198.25 | 8.4% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $173.61 | 7.4% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $153.31 | 6.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.57 | 6.3% | 7 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $104.19 | 4.4% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $99.61 | 4.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $98.58 | 4.2% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.97 | 3.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $89.12 | 3.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.41 | 3.5% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $81.62 | 3.5% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $46.44 | 2.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.78 | 1.9% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $31.76 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.02 | 1.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.01 | 1.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.40 | 0.9% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $19.38 | 0.8% | 1 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $18.29 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.07 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.13 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,348.83 | 107 |
| Education | $8.24 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $553.98 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $212.57 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $189.74 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $182.46 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $153.31 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $147.57 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $147.57 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $104.19 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $98.58 | 5 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $90.97 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $89.12 | 4 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $81.62 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $81.62 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $78.18 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.00 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $46.44 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $44.78 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $31.76 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.02 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.01 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 16 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 160 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOVANTIK movantik |
2025 | Movantik | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
47 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
160 | 24 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
250 | 32 |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 101 |
| Lisinopril | Lisinopril | 516 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 492 | 70 |
| Meloxicam | Meloxicam | 469 | 100 |
| Furosemide | Furosemide | 459 | 75 |
| Losartan Potassium | Losartan Potassium | 443 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 420 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 408 | 49 |
| Gabapentin | Gabapentin | 394 | 62 |
| Potassium Chloride | Potassium Chloride | 346 | 54 |
| Oxycodone Hcl | Oxycodone Hcl | 306 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 280 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 37 |
| Alprazolam | Alprazolam | 266 | 32 |
| Baclofen | Baclofen | 255 | 57 |
| Mirtazapine | Mirtazapine | 252 | 31 |
| Eliquis | Apixaban | 250 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 237 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 52 |
| Allopurinol | Allopurinol | 228 | 48 |
| Sertraline Hcl | Sertraline Hcl | 228 | 32 |
| Trazodone Hcl | Trazodone Hcl | 222 | 39 |
| Methadone Hcl | Methadone Hcl | 221 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 211 | 54 |
| Omeprazole | Omeprazole | 192 | 33 |
| Metformin Hcl | Metformin Hcl | 180 | 47 |
| Carvedilol | Carvedilol | 173 | 35 |
| Donepezil Hcl | Donepezil Hcl | 172 | 18 |
| Montelukast Sodium | Montelukast Sodium | 172 | 25 |
| Famotidine | Famotidine | 167 | 32 |
| Entresto | Sacubitril/Valsartan | 160 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 145 | 26 |
| Levofloxacin | Levofloxacin | 141 | 96 |
| Finasteride | Finasteride | 138 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 22 |
| Levetiracetam | Levetiracetam | 131 | 12 |
| Memantine Hcl | Memantine Hcl | 117 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 15 |
| Diazepam | Diazepam | 109 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 32 |
| Ozempic | Semaglutide | 103 | 16 |
| Prednisone | Prednisone | 102 | 43 |
| Lorazepam | Lorazepam | 100 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 98 | 13 |
| Xarelto | Rivaroxaban | 95 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 18 |
| Januvia | Sitagliptin Phosphate | 92 | 14 |
| Azithromycin | Azithromycin | 91 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 21 |
| Myrbetriq | Mirabegron | 91 | 11 |
| Pregabalin | Pregabalin | 84 | 14 |
| Glimepiride | Glimepiride | 83 | 26 |
| Tramadol Hcl | Tramadol Hcl | 83 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 20 |
| Buspirone Hcl | Buspirone Hcl | 81 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | 14 |
| Spironolactone | Spironolactone | 75 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 43 |
| Olanzapine | Olanzapine | 73 | 13 |
| Carisoprodol | Carisoprodol | 71 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 71 | 12 |
| Nystatin | Nystatin | 70 | 21 |
| Simvastatin | Simvastatin | 69 | 12 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | suppressed |
| Jardiance | Empagliflozin | 66 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | suppressed |
| Aripiprazole | Aripiprazole | 64 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 63 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 16 |
| Fluconazole | Fluconazole | 58 | 29 |
| Synthroid | Levothyroxine Sodium | 58 | suppressed |
| Digoxin | Digoxin | 56 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Estradiol | Estradiol | 46 | suppressed |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Lovastatin | Lovastatin | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Latanoprost | Latanoprost | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 26 |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Fentanyl | Fentanyl | 39 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Amoxicillin | Amoxicillin | 36 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | 17 |
| Lidocaine | Lidocaine | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 22 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Lacosamide | Lacosamide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Ursodiol | Ursodiol | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Galantamine Er | Galantamine Hbr | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 19 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 15 |
| Sucralfate | Sucralfate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 14 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Xolair | Omalizumab | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,357.07 · 108 records | JAZZ PHARMACEUTICALS INC. | AIRSUPRA, AREXVY, ARISTADA, CAPLYTA, Cologuard Collection Kit, ENTRESTO, EPIDIOLEX, Hillrom - Vest System Model 105 Home Care, IBSRELA, JOURNAVX, LEQVIO, LYBALVI, MOUNJARO, MOVANTIK, NURTEC ODT, NUZYRA, Ozempic, QULIPTA, REXULTI, ROXYBOND, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error